---
title: Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
date: '2024-05-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38804517/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240528181550&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: In this randomized, controlled trial involving participants
  with mixed hyperlipidemia, plozasiran, as compared with placebo, significantly reduced
  triglyceride levels at 24 weeks. A clinical outcomes trial is warranted. (Funded
  by Arrowhead Pharmaceuticals; MUIR ClinicalTrials.gov number ...'
disable_comments: true
---
CONCLUSIONS: In this randomized, controlled trial involving participants with mixed hyperlipidemia, plozasiran, as compared with placebo, significantly reduced triglyceride levels at 24 weeks. A clinical outcomes trial is warranted. (Funded by Arrowhead Pharmaceuticals; MUIR ClinicalTrials.gov number ...